drugset / Trial / NCT06300424
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
NaSingle-groupOpen-labelTreatment
Summary
Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in EGFR-mutant stage IIA-IIIB NSCLC followed by surgery, adjuvant treatment was upon investigators' decisions.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-01-26
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | 110 mg | — |
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | — |